Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Neoplasms, Plasma Cell 1Lymphoma 1Leukemia 1Hematologic Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 50fludarabine phosphate 47Busulfan 46Cyclosporine 36Antilymphocyte Serum 33Cytarabine 32Peripheral Blood Stem Cell Transplantation 30Radiotherapy 28Filgrastim 27Methotrexate 23Melphalan 23Mycophenolic Acid 21Cord Blood Stem Cell Transplantation 21Methylprednisolone 20Etoposide 17Whole-Body Irradiation 16Tacrolimus 15Daunorubicin 11Epoetin Alfa 10fludarabine 9Thiotepa 9Alemtuzumab 8Idarubicin 7Granulocyte Colony-Stimulating Factor 7sargramostim 6Topotecan 6Mitoxantrone 6Azacitidine 6Arsenic Trioxide 6Gemtuzumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia × Glycopeptides × Classical hematology × Clear all
NCT00195533 2009-11-16

Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients

Wyeth is now a wholly owned subsidiary of Pfizer

Completed
801 enrolled
Classical hematologyLymphoidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Leukemia, Lymphoma, Hematologic Neoplasms, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡